Movatterモバイル変換


[0]ホーム

URL:


GB840870A - Improvements in or relating to insulin preparations - Google Patents

Improvements in or relating to insulin preparations

Info

Publication number
GB840870A
GB840870AGB22705/58AGB2270558AGB840870AGB 840870 AGB840870 AGB 840870AGB 22705/58 AGB22705/58 AGB 22705/58AGB 2270558 AGB2270558 AGB 2270558AGB 840870 AGB840870 AGB 840870A
Authority
GB
United Kingdom
Prior art keywords
insulin
solution
exceed
zinc
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB22705/58A
Inventor
Jorgen Schlichtkrull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Terapeutisk Laboratorium AS
Original Assignee
Novo Terapeutisk Laboratorium AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Terapeutisk Laboratorium ASfiledCriticalNovo Terapeutisk Laboratorium AS
Publication of GB840870ApublicationCriticalpatent/GB840870A/en
Expiredlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

A quick-acting insulin preparation is prepared by dissolving insulin derived from pig pancreas in an aqueous injectable medium having or being given a pH value of between 7 and 8. A solution of a compound of one or more metals that are prerequisite to the crystallization of insulin, i.e. zinc, cobalt, nickel or cadmium may be added providing the total metal content of the solution does not exceed about 13 X A X 10-13 milli equivalents per litre, A being the number of international units of insulin per millilitic. Buffering agents, for example, phosphate, citrate, acetate, borate, maleate, diethyl barbiturate and glycerol buffers may also be present. If the buffer used is capable of forming complexes with the metal ions present, the amount of metal compound added may exceed the above stated amount providing the free metal ions in solution do not exceed the limit. An example given is the preparation of an 0.02M aqueous solution of sodium acetate containing per litre 1.74 gms. (40,000 international units) of crystalline insulin derived from pig pancreas and containing about 0.7% zinc, 2 ml. N hydrochloric acid, 1 gm. methyl-p-hydroxybenzoate, 1.4% by weight NaCl, the pH being adjusted to 7.3 to 7.5 with sodium hydroxide.
GB22705/58A1957-08-031958-07-15Improvements in or relating to insulin preparationsExpiredGB840870A (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
DK840870X1957-08-03

Publications (1)

Publication NumberPublication Date
GB840870Atrue GB840870A (en)1960-07-13

Family

ID=8153224

Family Applications (1)

Application NumberTitlePriority DateFiling Date
GB22705/58AExpiredGB840870A (en)1957-08-031958-07-15Improvements in or relating to insulin preparations

Country Status (3)

CountryLink
CY (1)CY217A (en)
GB (1)GB840870A (en)
MY (1)MY6100048A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2014118355A1 (en)2013-02-042014-08-07SanofiStabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104311A1 (en)*2014-01-092015-07-16SanofiStabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9526764B2 (en)2008-10-172016-12-27Sanofi-Aventis Deutschland GmbhCombination of an insulin and a GLP-1-agonist
US9707176B2 (en)2009-11-132017-07-18Sanofi-Aventis Deutschland GmbhPharmaceutical composition comprising a GLP-1 agonist and methionine
US9821032B2 (en)2011-05-132017-11-21Sanofi-Aventis Deutschland GmbhPharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9839692B2 (en)2014-01-092017-12-12SanofiStabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895423B2 (en)2014-01-092018-02-20SanofiStabilized pharmaceutical formulations of insulin aspart
US9950039B2 (en)2014-12-122018-04-24Sanofi-Aventis Deutschland GmbhInsulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en)2010-08-302018-05-29Sanofi-Aventis Deutschland GmbhUse of AVE0010 for the treatment of diabetes mellitus type 2
US9987332B2 (en)2011-09-012018-06-05Sanofi-Aventis Deutschland GmbhPharmaceutical composition for use in the treatment of a neurodegenerative disease
US10029011B2 (en)2009-11-132018-07-24Sanofi-Aventis Deutschland GmbhPharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en)2015-03-182018-12-25Sanofi-Aventis Deutschland GmbhTreatment of type 2 diabetes mellitus patients
US10434147B2 (en)2015-03-132019-10-08Sanofi-Aventis Deutschland GmbhTreatment type 2 diabetes mellitus patients

Cited By (23)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US10117909B2 (en)2008-10-172018-11-06Sanofi-Aventis Deutschland GmbhCombination of an insulin and a GLP-1 agonist
US9526764B2 (en)2008-10-172016-12-27Sanofi-Aventis Deutschland GmbhCombination of an insulin and a GLP-1-agonist
US12303598B2 (en)2009-11-132025-05-20Sanofi-Aventis Deutschland GmbhPharmaceutical composition comprising a GLP-1-agonist and methionine
US9707176B2 (en)2009-11-132017-07-18Sanofi-Aventis Deutschland GmbhPharmaceutical composition comprising a GLP-1 agonist and methionine
US10029011B2 (en)2009-11-132018-07-24Sanofi-Aventis Deutschland GmbhPharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10028910B2 (en)2009-11-132018-07-24Sanofi-Aventis Deutschland GmbhPharmaceutical composition comprising a GLP-1-agonist and methionine
US9981013B2 (en)2010-08-302018-05-29Sanofi-Aventis Deutschland GmbhUse of AVE0010 for the treatment of diabetes mellitus type 2
US9821032B2 (en)2011-05-132017-11-21Sanofi-Aventis Deutschland GmbhPharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9987332B2 (en)2011-09-012018-06-05Sanofi-Aventis Deutschland GmbhPharmaceutical composition for use in the treatment of a neurodegenerative disease
EP3747426A1 (en)2013-02-042020-12-09SanofiStabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2014118355A1 (en)2013-02-042014-08-07SanofiStabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9839675B2 (en)2013-02-042017-12-12SanofiStabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9839692B2 (en)2014-01-092017-12-12SanofiStabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895423B2 (en)2014-01-092018-02-20SanofiStabilized pharmaceutical formulations of insulin aspart
CN105899191A (en)*2014-01-092016-08-24赛诺菲 Stabilized glycerol-free pharmaceutical preparations of insulin analogues and/or insulin derivatives
US10610595B2 (en)2014-01-092020-04-07SanofiStabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105899191B (en)*2014-01-092020-06-16赛诺菲Stabilized glycerol-free pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895424B2 (en)2014-01-092018-02-20SanofiStabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104311A1 (en)*2014-01-092015-07-16SanofiStabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9950039B2 (en)2014-12-122018-04-24Sanofi-Aventis Deutschland GmbhInsulin glargine/lixisenatide fixed ratio formulation
US12186374B2 (en)2014-12-122025-01-07Sanofi-Aventis Deutschland GmbhInsulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en)2015-03-132019-10-08Sanofi-Aventis Deutschland GmbhTreatment type 2 diabetes mellitus patients
US10159713B2 (en)2015-03-182018-12-25Sanofi-Aventis Deutschland GmbhTreatment of type 2 diabetes mellitus patients

Also Published As

Publication numberPublication date
MY6100048A (en)1961-12-31
CY217A (en)1961-03-27

Similar Documents

PublicationPublication DateTitle
GB840870A (en)Improvements in or relating to insulin preparations
GB1214733A (en)A method for the preparation of stannous salt/palladium compositions
Kinsky et al.Neurospora nitrate reductase: The role of phosphate, flavine and cytochrome c reductase
GB1463966A (en)Depilatory formulation
ES263099A2 (en)Stabilized galactomannan gum solutions and process
GB1160314A (en)Acidified Hydrogen Peroxide Solutions for Dissolving Metals
JPS5642970A (en)Redox battery
GB718574A (en)Bath for the deposit of gold alloys by electroplating
GB1038678A (en)Compounds having an adrenocorticotrophic hormone action and process for their manufacture
GB907303A (en)Improvements in or relating to the production of semi-conductor devices
GB1310610A (en)Electro-less nickel plating compositions
Jaffe et al.Studies on prolactin inhibition of thyroxine-induced metamorphosis in Rana catesbeiana tadpoles
GB835638A (en)Insulin crystal suspensions having a protracted effect
US2695860A (en)Stabilized pteroyl solutions
GB1247980A (en)Copper alloy cleaning process
GB748857A (en)Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity
GB889769A (en)Slowly acting insulin preparation in crystalline form
GB1488807A (en)Agents for the selective combating of weeds
GB929220A (en)Gold plating
ES464642A1 (en)Preparations of 3-n-pyrrolidino-4-phenoxy-5-sulphamyl-benzolc acid and process for their manufacture
GB594355A (en)Improvements in or relating to silver solder alloys
GB709927A (en)Improved process for producing insulin preparations with protracted effect
GB1386584A (en)Method of preparation of purine sugar derivatives
GB1492106A (en)Gelatine dessert composition
GB708888A (en)Improved process for producing injectable insulin preparations with protracted effect

[8]ページ先頭

©2009-2025 Movatter.jp